Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved teclistamab in combination with daratumumab hyaluronidase on 5 March for adults with relapsed or refractory multiple myeloma.
The indication covers patients who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Multiple myeloma treatment continues to move combinations earlier in the disease course as regulators evaluate whether advanced immunotherapies can improve outcomes after fewer prior therapies.
Sourcing note: Indication details are from FDA. The article does not make claims about comparative sequencing beyond the approved indication.
Why It Matters
Earlier-line approval for advanced myeloma combinations can affect treatment planning quickly, because clinicians are choosing among many targeted, antibody and cellular approaches. The key question is how benefit, toxicity and access play out outside trials.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDATeclistamabDaratumumabMultiple MyelomaOncology